Paper Details

  1. Home
  2. Paper Details

The Role of Non-genetic Therapies to Reduce the Incidence of Sickle Cell Crisis: A Systematic Review.

Author: AwosusiBabatope L, AyyubJavaria, DabhiKaran Nareshbhai, GohilNamra V, HamidPousette, HusseinSally, JaramilloArturo P, MakkenaVijaya Krishna, PingiliShravya, TanveerNida

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review discusses seven interventions used to treat sickle cell disease. Voxelotor, crizanlizumab, L-glutamate, long-term blood transfusions, zinc, Niprisan®, and Ciklavit* were found to reduce the number and severity of vaso-occlusive crises (VOCs). L-glutamate also reduced the length of hospitalization. More clinical trials are needed to evaluate the dosages and outcomes of using these drugs in combination to prevent VOCs.
Paper Details　
Original Abstract of the Article :
Sickle cell anemia is a hemoglobinopathy that causes complications such as Vaso-Occlusive Crisis (VOC), stroke, priapism, Acute Chest Syndromes (ACS), and bone infarcts due to blood vessel occlusion, resulting in hypoxia, ischemia, and inflammation. Preventing these incidents improves the quality of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469705/

データ提供：米国国立医学図書館（NLM）

Sickle Cell Disease: Searching for Solutions in a Desert of Pain

Sickle cell anemia is a serious inherited blood disorder that can lead to debilitating complications, including vaso-occlusive crisis (VOC), stroke, and acute chest syndromes. This study explores the potential of non-genetic therapies to reduce the incidence of sickle cell crisis, aiming to improve the quality of life and survival rates for patients with sickle cell disease (SCD).

A Quest for Relief: Exploring Non-Genetic Therapies

The study reviewed recent research on various non-genetic therapies for SCD, including voxelotor, crizanlizumab, L-glutamate, long-term blood transfusions, zinc, Niprisan®, and Ciklavit*. The study found evidence that these therapies can reduce the number and severity of VOC, delay the time for the next VOC, and decrease the length of hospitalization.

Navigating the Desert: The Importance of Ongoing Research

The study highlights the need for ongoing research to evaluate the effectiveness and safety of these therapies. The researchers emphasize the importance of conducting large-scale clinical trials to further investigate the optimal dosages and combinations of these therapies to maximize their benefits.

Dr. Camel's Conclusion

This systematic review provides a valuable overview of non-genetic therapies for sickle cell disease. The researchers highlight the potential of these therapies to reduce the incidence of sickle cell crisis and improve the quality of life for patients. However, they also emphasize the need for continued research to optimize these treatments and ensure their safety and effectiveness. This study represents a significant step forward in the search for solutions in the desert of sickle cell disease.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-09-05
Further Info :

Pubmed ID

37664256

DOI: Digital Object Identifier

PMC10469705

Related Literature

Article Analysis
・Side Effects of voxelotor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.